Global Diabetic Neuropathy Drugs Market 2019-2023
SKU ID : TNV-14098783 | Publishing Date : 28-Mar-2019 | No. of pages : 135
Detailed TOC of Global Diabetic Neuropathy Drugs Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: CUSTOMER LANDSCAPE
PART 07: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 08: MARKET SEGMENTATION BY MECHANISM OF ACTION
• Market segmentation by mechanism of action
• Comparison by mechanism of action
• Calcium channel alpha-2-delta ligand - Market size and forecast 2018-2023
• SNRIs and TCAs - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by mechanism of action
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
• Market trends
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• DAIICHI SANKYO COMPANY, LIMITED
• Eli Lilly and Company
• Johnson & Johnson Services, Inc.
• Novartis AG
• Pfizer Inc.
PART 13: APPENDIX
• Research methodology
• List of abbreviations
Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Customer landscape
Exhibit 19: Market share by geography 2018-2023 (%)
Exhibit 20: Geographic comparison
Exhibit 21: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: North America - Year-over-year growth 2019-2023 (%)
Exhibit 23: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 25: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 27: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 29: Key leading countries
Exhibit 30: Market opportunity
Exhibit 31: Mechanism of action - Market share 2018-2023 (%)
Exhibit 32: Comparison by mechanism of action
Exhibit 33: Calcium channel alpha-2-delta ligand - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Calcium channel alpha-2-delta ligand - Year-over-year growth 2019-2023 (%)
Exhibit 35: SNRIs and TCAs - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: SNRIs and TCAs - Year-over-year growth 2019-2023 (%)
Exhibit 37: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Others - Year-over-year growth 2019-2023 (%)
Exhibit 39: Market opportunity by mechanism of action
Exhibit 40: Decision framework
Exhibit 41: Pipeline drugs for diabetic neuropathy
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Biologics under development
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor_analysis1
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: DAIICHI SANKYO COMPANY, LIMITED - Vendor overview
Exhibit 51: DAIICHI SANKYO COMPANY, LIMITED - Business segments
Exhibit 52: DAIICHI SANKYO COMPANY, LIMITED - Organizational developments
Exhibit 53: DAIICHI SANKYO COMPANY, LIMITED - Geographic focus
Exhibit 54: DAIICHI SANKYO COMPANY, LIMITED - Segment focus
Exhibit 55: DAIICHI SANKYO COMPANY, LIMITED - Key offerings
Exhibit 56: Eli Lilly and Company - Vendor overview
Exhibit 57: Eli Lilly and Company - Business segments
Exhibit 58: Eli Lilly and Company - Organizational developments
Exhibit 59: Eli Lilly and Company - Geographic focus
Exhibit 60: Eli Lilly and Company - Segment focus
Exhibit 61: Eli Lilly and Company - Key offerings
Exhibit 62: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 63: Johnson & Johnson Services, Inc. - Business segments
Exhibit 64: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 65: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 66: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 67: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 68: Novartis AG - Vendor overview
Exhibit 69: Novartis AG - Business segments
Exhibit 70: Novartis AG - Organizational developments
Exhibit 71: Novartis AG - Geographic focus
Exhibit 72: Novartis AG - Segment focus
Exhibit 73: Novartis AG - Key offerings
Exhibit 74: Pfizer Inc. - Vendor overview
Exhibit 75: Pfizer Inc. - Business segments
Exhibit 76: Pfizer Inc. - Organizational developments
Exhibit 77: Pfizer Inc. - Geographic focus
Exhibit 78: Pfizer Inc. - Segment focus
Exhibit 79: Pfizer Inc. - Key offerings
Exhibit 80: Validation techniques employed for market sizing
Exhibit 81: List of abbreviations
Keyplayers in Global Diabetic Neuropathy Drugs Market 2019-2023
DAIICHI SANKYO COMPANY, LIMITEDEli Lilly and Company
Johnson & Johnson Services, Inc.
Novartis AG
Pfizer Inc.